印度的国家方案通过确保负担得起的优质药品,将试点邦的高血压控制提高到70-81%。 India’s national program boosted hypertension control to 70–81% in pilot states by ensuring affordable, quality medicines.

世界卫生组织的《2025年超高血压问题全球报告》赞扬印度通过2018-2019年发起的全国免费药品服务倡议和印度超高血压控制倡议,在改善血压控制方面取得了成功。 The World Health Organization’s 2025 Global Report on Hypertension praised India’s success in improving blood pressure control through its National Free Drugs Service Initiative and the India Hypertension Control Initiative, launched in 2018–2019. 通过确保通过公共诊所和Jan-Aushadhi商店稳定供应负担得起的、有质量保证的非专利药品,以及执行国家药品定价管理局规定的价格上限,印度大幅度减少了自费费用——最高可达80,并改进了获得服务的机会。 By ensuring a steady supply of affordable, quality-assured generic medicines via public clinics and Jan-Aushadhi stores, and implementing price ceilings set by the National Pharmaceutical Pricing Authority, India significantly reduced out-of-pocket costs—by up to 80%—and improved access. 在旁遮普邦和马哈拉施特拉邦等试点邦,接受治疗的病人的高血压控制率上升到70-81%,静脉血压下降了15-16毫米Hg。 In pilot states like Punjab and Maharashtra, hypertension control rates among treated patients rose to 70–81%, with systolic blood pressure dropping by 15–16 mmHg. 这些努力增进了健康成果,降低了长期心血管费用,并显示出较高的公共卫生价值。 These efforts enhanced health outcomes, reduced long-term cardiovascular costs, and demonstrated high public health value. 2024年全球有14亿人高血压,但控制高血压的人不到五分之一,99个国家报告控制率低于20%,只有28%的低收入国家持续获得基本药物。 Globally, 1.4 billion people had hypertension in 2024, yet fewer than one in five had it controlled, with 99 countries reporting control rates below 20% and only 28% of low-income nations having consistent access to essential medicines. 世卫组织为其他国家建议了类似的战略。 The WHO recommends similar strategies for other nations.